Jun 93 minNew consortium EUbOPEN will provide tools to unlock disease biology66 million euros to generate open-access chemical tools Frankfurt and Ingelheim, Germany – 08 June 2020 – Almost twenty years after deci...
Jun 22 minTwist Bioscience to join Proteona to protect immunocompromised patients from COVID-19 infection.Singapore, June 1st 2020 - Proteona today announced that Twist Bioscience (Nasdaq: TWST) will join the international alliance led by Prot...
May 142 minUnderstanding the role of our genes in SARS-CoV-2 infectionsEMBL scientists will contribute to the new German COVID-19 OMICS Initiative to study the biological mechanisms contributing to coronavi...
May 122 minProteona’s ESCAPE™ platform selected for SARS-CoV-2 vaccine characterizationSingapore, May 12th 2020 - Proteona announced today that it is beginning a partnership with Professor Nikolai Petrovsky from Flinders Uni...
Mar 234 minOne more step towards true precision medicineProteona, Synovo, and NMI announced collaboration on a single cell multi-omics profiling platform for patient-derived micro-tumors Singap...
Mar 122 min€2.45 m to investigate leukaemia causes and therapiesThe Heidelberg-based LeukoSyStem consortium investigates leukaemia stem cells in acute myeloid leukaemia. The German Federal Ministry of...
Feb 201 minArtificial pericardial tissue from the 3D printerTogether with its project partners, the NMI can already report initial successes in the PolyKARD project, specifically the synthesis and ...
Jan 141 minBioMed X starts new schizophrenia research program with Boehringer IngelheimHeidelberg, Germany, January 13th, 2020 – BioMed X announced today the start of a new joint research group in collaboration with Boehri...
Jan 102 minBausch Health licenses Novaliq’s NOV03 investigational treatment for dry eye disease Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq Gmb...
Jan 101 minBioMed X starts new research program in autoimmune diseases with MerckHeidelberg, Germany, January 9th, 2020 – BioMed X announced today the start of a new joint research group in collaboration with Merck. ...
Jan 82 minVelabs Therapeutics and alytas enter into a licence agreement for senescenceVelabs Therapeutics receives exclusive licence from alytas therapeutics for the development of therapeutic antibodies as senolytics Heide...
Jan 72 minNeuro-Sys and Sciomics announce Partnership AgreementNeuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders...
Dec 5, 20192 minEMBL and Leica sign open innovation agreementLeica Microsystems and EMBL have signed a unique long-term framework collaboration agreement to provide new imaging technologies. The a...
Sep 24, 20192 minBioMed X successfully completes collaboration on development of nanomaterial-based biosensorsHeidelberg, Germany, September 23, 2019 – BioMed X announced today the completion of their first research collaboration project with Ro...
Sep 20, 20192 minHeidelberg Pharma receives European Union research grant for the ETN MAGICBULLET project Ladenburg, 19 September 2019 – Heidelberg Pharma AG (FSE : WL6) today announced that its subsidiary Heidelberg Pharma Research GmbH wil...
Sep 12, 20192 minPROGEN secures exclusive rights for AAV products from the German Cancer Research Center (DKFZ)Extensive licenses for research antibodies and test systems strengthen position in the gene therapy market. Heidelberg, 12.09.2019 – PROG...
Jul 31, 20191 minYUMAB announces new research & collaboration agreement with MerckYUMAB GmbH, a privately-held German biotechnology company, and Merck, a leading science and technology company, have signed a resear...
Apr 11, 20191 minPhenex collaborates with Mathias Heikenwaelder ́s research group from DKFZThe biotech company and Prof. Dr. Heikenwälder see common ground for joint research projects in NASH and cancer metabolism Phenex Pharma...
